147 related articles for article (PubMed ID: 429128)
1. Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. II. Immunodepressive effect of sera from bladder carcinoma.
Nishio S; Horii A; Morikawa Y; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
Invest Urol; 1979 Mar; 16(5):342-5. PubMed ID: 429128
[TBL] [Abstract][Full Text] [Related]
2. Studies of the nonspecific cellular immune response in patients with urinary bladder carcinoma. I. PHA-induced lymphocyte transformation.
Nishio S; Horii A; Morikawa Y; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
Invest Urol; 1979 Mar; 16(5):336-41. PubMed ID: 429127
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
Mizutani Y; Okada Y; Terachi T; Yoshida O
J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
[TBL] [Abstract][Full Text] [Related]
4. Immunocompetence of patients with transitional cell carcinoma as measured by dinitrochlorobenzene skin tests and in vitro lymphocyte function.
Bean MA; Schellhammer PS; Herr HW; Pinsky CM; Whitmore WF
Natl Cancer Inst Monogr; 1978 Dec; (49):111-4. PubMed ID: 155219
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
6. [Studies of the cellular immune response in patients with urinary bladder carcinoma. X. Evaluation of serum IAP and ASP levels].
Nishio S; Ozaki Y; Wada S; Kawakita J; Maekawa M
Hinyokika Kiyo; 1984 Apr; 30(4):449-57. PubMed ID: 6485956
[TBL] [Abstract][Full Text] [Related]
7. Studies on nonspecific cellular immune response in patients with urinary bladder carcinoma.
Nishio S; Morikawa Y; Horii A; Kawakita J; Nishijima T; Kishimoto T; Maekawa M
Osaka City Med J; 1978; 24(1):51-71. PubMed ID: 752146
[No Abstract] [Full Text] [Related]
8. In vitro immune parameters in relation to clinical course in transitional cell carcinoma.
Cummings KB; Kodera Y; Bean MA
Natl Cancer Inst Monogr; 1978 Dec; (49):119-22. PubMed ID: 155220
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma.
Kastelan Z; Lukac J; Derezić D; Pasini J; Kusić Z; Sosić H; Kastelan M
Anticancer Res; 2003; 23(6D):5185-9. PubMed ID: 14981987
[TBL] [Abstract][Full Text] [Related]
10. [Influence of a bovine calf thymic humoral factor on the non-specific cellular immune response of bladder carcinoma patients].
Horii A
Hinyokika Kiyo; 1987 Mar; 33(3):364-74. PubMed ID: 3497526
[TBL] [Abstract][Full Text] [Related]
11. Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum.
Newberry WM; Sanford JP
J Clin Invest; 1971 Jun; 50(6):1262-71. PubMed ID: 5578233
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
13. Diminished lymphocyte responses to phytohemagglutinin in lung cancer.
Hadjipetrou-Kourounakis L; Tsougranis A
Biochem Exp Biol; 1980; 16(4):357-64. PubMed ID: 6285942
[TBL] [Abstract][Full Text] [Related]
14. Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients.
Spina CA; Dorey F; Vescera C; Brosman S; Fahey JL
Cancer Res; 1981 Nov; 41(11 Pt 1):4324-30. PubMed ID: 6458353
[TBL] [Abstract][Full Text] [Related]
15. Leukocyte migration inhibition in vitro in bladder carcinoma.
Lavergne JA; Lamm DL; Radwin HM; Harrington JT
Cancer Res; 1979 Jun; 39(6 Pt 1):1985-8. PubMed ID: 445398
[TBL] [Abstract][Full Text] [Related]
16. Mixed leukocyte culture reactivity of lymph node cells regional to transitional cell carcinoma of the bladder.
Herr HW; Bean MA; Whitmore WF
Natl Cancer Inst Monogr; 1978 Dec; (49):177-81. PubMed ID: 155221
[TBL] [Abstract][Full Text] [Related]
17. [The study of infiltrating lymphocytes in the tissues of bladder carcinoma].
Fujimoto Y; Hasegawa Y; Kato N; Sakai S; Kuriyama M; Kawada Y; Nishiura T; Takeuchi T; Isogai K
Hinyokika Kiyo; 1983 Sep; 29(9):1037-45. PubMed ID: 6610297
[TBL] [Abstract][Full Text] [Related]
18. [RBC and T lymphocyte subsets in patients with bladder carcinoma: immunological study].
Xu J; Zhang Y
Zhonghua Wai Ke Za Zhi; 1999 Feb; 37(2):113-6. PubMed ID: 11829798
[TBL] [Abstract][Full Text] [Related]
19. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
Loskog A; Tötterman TH; Böhle A; Brandau S
Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cytolytic effector cells in peripheral blood of healthy individuals and cancer patients. II. Cytotoxicity to allogeneic or autochthonous tumor cells in tissue culture.
Pape GR; Troye M; Perlmann P
J Immunol; 1977 Jun; 118(6):1925-30. PubMed ID: 325130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
